JenaValve Technology, Inc., developer and manufacturer of differentiated pericardial transcatheter aortic valve replacement (TAVR) systems for the treatment of aortic valve disease, announces the appointment of Peter L. Spadaro, Jr. to the newly created position of Chief Commercial Officer. Mr. Spadaro is a highly accomplished cardiovascular sales and marketing executive who has held senior positions at global industry leaders including Medtronic, St. Jude Medical and most recently Syncardia.
“Peter’s proven success in all aspects of launching and commercializing innovative structural heart devices in the U.S. and internationally clearly makes him the ideal professional to lead this key function at JenaValve as we progress toward commercialization of our technology,” said JenaValve CEO John Kilcoyne. “He brings us unrivaled industry experience including a stellar track record in commercial planning and tactical execution. Peter has the ability to identify and capitalize on market opportunities and brings to JenaValve long established relationships with cardiovascular